5. Oct 2026
Description
(AWP Alliance News) - Pfizer management used its Q2 2026 earnings call on Aug. 4 to lift full-year revenue guidance to USD 60.5 billion-USD 62.5 billion, citing stronger non-COVID demand while cutting expected COVID-19 revenue to about USD 4 billion from USD 5 billion. Incoming interim CFO Cecile Guégan reaffirmed adjusted diluted EPS guidance of USD 2.80-USD 3, including an about USD 0.10 hit tied to a USD 650 million acquired in-process R&D charge from the Innovent Biologics deal that closed in July.
Guégan said Q2 revenue was USD 15 billion, up 1% operationally, while adjusted diluted EPS was USD 0.77; GAAP loss per share was USD 0.04 after USD 4.3 billion of non-cash intangible impairments tied mainly to a Phase 3 setback for a Seagen lung cancer program. The Chief US Commercial Officer said Padcev revenue rose more than 20% in the quarter, with locally advanced or metastatic new patient share above 60%, while management pointed to an FDA label expansion into muscle-invasive bladder cancer and a new Phase 3 bladder-sparing study as key growth drivers.
The CEO said the dividend would be maintained through the loss-of-exclusivity period, with bolt-on business development expected within remaining capacity of about USD 6 billion-USD 7 billion.
https://docs.publicnow.com/F6F418702148FE3B6DBFA6F7305ABE54F9F19220
Disclaimer: This news brief was created using generative artificial intelligence. Pfizer Inc. published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.
